Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis

por Ilan, Yaron, Ben Ya'acov, Ami, Shabbat, Yehudit, Gingis-Velitski, Svetlana, Almon, Einat, Shaaltiel, Yoseph
Publicado 2016

Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story

por Rup, Bonita, Alon, Sari, Amit-Cohen, Bat-Chen, Brill Almon, Einat, Chertkoff, Raul, Tekoah, Yoram, Rudd, Pauline M.
Publicado 2017

A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation

por Aviezer, David, Brill-Almon, Einat, Shaaltiel, Yoseph, Hashmueli, Sharon, Bartfeld, Daniel, Mizrachi, Sarah, Liberman, Yael, Freeman, Arnold, Zimran, Ari, Galun, Eithan
Publicado 2009

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

por Pastores, Gregory M., Shankar, Suma P., Petakov, Milan, Giraldo, Pilar, Rosenbaum, Hanna, Amato, Dominick J., Szer, Jeffrey, Chertkoff, Raul, Brill‐Almon, Einat, Zimran, Ari
Publicado 2016

Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis: Results From a Phase 2a Clinical Trial

por Almon, Einat, Shaaltiel, Yoseph, Sbeit, Wisam, Fich, Alex, Schwartz, Doron, Waterman, Mattitiahu, Szlaifer, Mali, Reuveni, Hadar, Amit-Cohen, Bat-chen, Alon, Sari, Chertkoff, Raul, Paz, Alona, Ilan, Yaron
Publicado 2021

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study

por Linhart, Aleš, Dostálová, Gabriela, Nicholls, Kathy, West, Michael L., Tøndel, Camilla, Jovanovic, Ana, Giraldo, Pilar, Vujkovac, Bojan, Geberhiwot, Tarekegn, Brill-Almon, Einat, Alon, Sari, Chertkoff, Raul, Rocco, Rossana, Hughes, Derralynn
Publicado 2023

Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease

por Zimran, Ari, Durán, Gloria, Mehta, Atul, Giraldo, Pilar, Rosenbaum, Hanna, Giona, Fiorina, Amato, Dominick J., Petakov, Milan, Muñoz, Eduardo Terreros, Solorio‐Meza, Sergio Eduardo, Cooper, Peter A., Varughese, Sheeba, Chertkoff, Raul, Brill‐Almon, Einat
Publicado 2016